Details of the Drug

General Information of Drug (ID: DMKGSWM)

Drug Name
EB-1020
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Phase 2 [1]
Structure
3D MOL is unavailable 2D MOL
Chemical Identifiers
Formula
C15H16ClN
Canonical SMILES
C1C2C1(CNC2)C3=CC4=CC=CC=C4C=C3.Cl
InChI
InChI=1S/C15H15N.ClH/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15;/h1-7,14,16H,8-10H2;1H/t14-,15+;/m1./s1
InChIKey
ACVMJAJGCQUPKX-LIOBNPLQSA-N
Cross-matching ID
PubChem CID
68943792
CAS Number
923981-14-0
TTD ID
D03AYQ

References

1 ClinicalTrials.gov (NCT01939353) An Exploratory, Single-Blind Pilot Study Of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder. U.S. National Institutes of Health.